Clinical trials: Kidney Tumors
Tuberous Sclerosis Complex (TSC)
Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients With Tuberous Sclerosis
Observational, retrospective, multicenter, nonprofit study on the prevalence of renal involvement in pediatric patients with tuberous sclerosis.
- Trial name
- NCT06764602
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Renal Cell Carcinoma
Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients With Renal Cell Carcinoma
The aim of this study is to determine the utility of renal ultrasonography (US) in the detection of abdominal recurrences after definitive therapy for renal cell carcinoma (RCC) and compare the detection rate to that of…
- Trial name
- NCT04424472
- Testing
- Ultrasonography
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Kansas Medical Center
Kidney Transplant; Complications
Immunosuppression's Long Term Impact on Anti-tumoral Oversight in Kidney Transplantation
Cancer is a well known complication about long term transplantation. Cancer outcomes are due to the immunosuppressive treatment that prevents transplanted people from rejection.
- Trial name
- NCT03227965
- Testing
- Immune cells population assesment
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Poitiers University Hospital
Hypertension, Depression
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
The aim of Patient-Centred Innovations for Persons With Multimorbidity (PACE in MM) study is to reorient the health care system from a single disease focus to a multimorbidity focus; centre on not only disease but also the…
- Conditions
- Hypertension, Depression, Anxiety, Musculoskeletal Pain
- Trial name
- PACEinMM-QC (NCT02789800)
- Testing
- DIMAC02
- Where
- 2 sites in Canada
- Volunteers
- 284 people
- Sponsor
- Université de Sherbrooke
Renal Cell Carcinoma
Novel Prognostic Markers in Renal Cancer
The purpose of this project is to analyze tumour tissue from a group of subjects with renal cell carcinoma, who have been treated at the Royal Marsden Hospital.
- Trial name
- NCT01002937
- Where
- United Kingdom
- Volunteers
- 182 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non Small Cell Lung Cancer, Mesothelioma
Dose Individualization of Pemetrexed - IMPROVE-III
Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma.
- Trial name
- IMPROVE-III (NCT03655834)
- Testing
- Pemetrexed
- Where
- 5 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Urothelial Carcinoma
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
- Trial name
- NCT01234519
- Testing
- AEZS-108, AEZS-108 at MTD
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- AEterna Zentaris
Misoprostol Allergy, Oxytocin Allergy
Methods Decreasing Bleeding in Open Myomectomy
Uterine leiomyomas (fibroids or myomas) are benign, smooth muscle tumors of the human uterus. Most myomas are asymptomatic (symptomless) and are discovered incidentally during a routine pelvic examination or imaging studies and…
- Conditions
- Misoprostol Allergy, Oxytocin Allergy, Tranexamic Acid Allergy, Ethamsylate Allergy
- Trial name
- NCT05806307
- Testing
- Misoprostol, Tourniquet, Carbetocin
- Where
- Egypt
- Volunteers
- 105 people
- Sponsor
- Cairo University
Carcinoma, Renal Cell
Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.
The aim of this study is to compare the efficacy (in terms of event-free survival and overall survival) of an adjuvant therapy with IFN-alpha plus low-dose of IL2 vs a wait-and-see program in patient with radically operated renal…
- Trial name
- NCT00502034
- Testing
- Interferon Alfa-2a, Interleukin-2
- Where
- 8 sites in Italy
- Volunteers
- 310 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Chemotherapeutic Agent Toxicity, Sarcoma
CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide
RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer treated with ifosfamide may help doctors identify risk factors for kidney damage.
- Conditions
- Chemotherapeutic Agent Toxicity, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00514345
- Testing
- gene expression analysis, polymorphism analysis, management of therapy complications
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 300 people
- Sponsor
- Children's Cancer and Leukaemia Group
Brain and Central Nervous System Tumors, Hereditary Wilms Tumor
Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer
RATIONALE: The identification of gene mutations in young patients with pleuropulmonary blastoma syndrome may allow doctors to better understand the genetic processes involved in the development of some types of cancer, and may…
- Conditions
- Brain and Central Nervous System Tumors, Hereditary Wilms Tumor, Kidney Cancer, Liver Cancer
- Trial name
- NCT01353300
- Testing
- DNA analysis, cytogenetic analysis, gene expression analysis
- Volunteers
- 31 people
- Sponsor
- Children's Oncology Group
Preference, Patient, Pharmacist-Patient Relations
Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital
To ensure the safe use of oral anticancer drugs, oncology pharmacy consultations (OPCs) have been established in France. Their goal is to provide the patient with the means to identify, prevent and limit adverse effects and to…
- Conditions
- Preference, Patient, Pharmacist-Patient Relations, Caregiver, Cancer
- Trial name
- IMPLICATION (NCT05970471)
- Where
- France
- Volunteers
- 167 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Advanced Solid Tumors
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
This trial will investigate the pharmacokinetics (PK) and safety of talazoparib in patients with advanced solid tumors and impaired renal function.
- Trial name
- NCT02997163
- Testing
- Talazoparib
- Where
- 10 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Pfizer
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Renal Cell Carcinoma
Study of CP-461 in Patients With Advanced Renal Cell Cancer
The purpose of this study is to determine the efficacy of CP-461 given twice-daily orally in locally advanced or metastatic renal cell cancer and to evaluate the safety profile of CP-461 in this patient population.
- Trial name
- NCT00036036
- Testing
- CP-461
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Inc
Renal Cell Carcinoma
Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma
The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of…
- Trial name
- TTV ccRCC (NCT07018037)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Regina Elena Cancer Institute
Kidney Neoplasms / Surgery, Glomerular Filtration Rate
The Study on the Effectiveness of [68Ga]Ga-HBED-CC-DiAsp PET/CT in Calculating GFR and Predicting Residual Renal Function After Partial Nephrectomy
In subjects with different levels of renal function and no history of renal tumors, GFR is measured using [68Ga]Ga-HBED-CC-DiAsp PET/CT, the Gates method, and the 99mTc-DTPA dual plasma method.
- Conditions
- Kidney Neoplasms / Surgery, Glomerular Filtration Rate, Positron-Emission Tomography(PET)
- Trial name
- NCT06973798
- Testing
- GFR will be measured using three methods at two weeks before surgery and four ± one week after surgery, GFR will be measured using three methods: [68Ga]Ga-HBED-CC-DiAsp PET/CT, the Gates method, and the dual plasma sampling method with 99mTc-DTPA.
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luo Yaping
Kidney Cancer
Randomized Clinical Trial Aimed at Comparing Unclamped Robotic Partial Nephrectomy With or Without Renorrhaphy
Intended to minimize ischemia during robotic partial nephrectomy (RPN) procedures "by any means possible". Before starting enucleation, the boundaries of the tumor are marked during SL-ocRPN surgery cautery.
- Trial name
- NCT06846112
- Testing
- Robotic partial nephrectomy
- Where
- Italy
- Volunteers
- 248 people
- Sponsor
- Regina Elena Cancer Institute
Renal Cell Carcinoma
Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)
Combined sunitinib and bevacizumab in advanced renal cell carcinoma.
- Trial name
- NCT02919371
- Testing
- Sunitinib, Bevacizumab
- Where
- Saudi Arabia
- Volunteers
- 77 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Renal Cell Carcinoma, Circulating Tumor Cell
Circulating Tumor Cell Reducing No-touch Nephrectomy
This study will study circulating tumor cell (CTC) release during laparoscopic radical nephrectomy (LRN) for RCC. The main objective is to determine if CTC release can be reduced during RN by using a no-touch technique, with an…
- Trial name
- CITO-CERENE (NCT05070637)
- Testing
- No-touch laparoscopic radical nephrectomy, Conventional laparoscopic radical nephrectomy, Laparoscopic total nephrectomy control arm
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- Hospital de Santa Maria, Portugal